AUTHOR: mara-admin

AEGEA Medical today announced it has received U.S. Food and Drug Administration (FDA) PMA Approval for and performed first commercial procedures with the next generation Mara™ Water Vapor Ablation System. Mara is the only endometrial ablation treatment that utilizes natural water vapor to safely treat heavy menstrual bleeding, specifically designed for use in the doctor’s office without the need for general anesthesia.

AEGEA Medical announced today the publication of the Post-Ablation Cavity Evaluation (PACE) clinical study in the Journal of Minimally Invasive Gynecology. The PACE study evaluated hysteroscopic access to the uterine cavity for women who previously underwent endometrial ablation for heavy menstrual bleeding as part of a pivotal trial of the company’s Mara™ Water Vapor Ablation System.

AEGEA Medical announced today that it has completed enrollment in the Post-Ablation Cavity Evaluation Mexico (PACE MX) clinical study of women who previously underwent endometrial ablation as part of a pivotal trial of AEGEA’s Mara™ Water Vapor Ablation Treatment. The PACE MX study is the third study of

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, has announced that 36-month follow-up data from a prospective, multicenter, pivotal study of its AEGEA Vapor System were presented at the AAGL Global Conference on Minimally Invasive Gynecologic Surgery in Las Vegas on November 13. The data showed that the AEGEA Vapor System is a safe, effective and minimally invasive option

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, announced that it has raised $17 million in financing led by Solas BioVentures and its affiliates. The proceeds will be used to fund AEGEA’s prospective, multi center Post-Ablation Cavity Access (PACE II) study to evaluate uterine cavity access and the possibility of minimally invasive interventions

AEGEA Medical, Inc. has announced the commencement of the Post-Ablation Cavity Evaluation (PACE II) clinical study in women who previously underwent endometrial ablation as part of AEGEA’s pivotal trial of the company’s patented Adaptive Vapor Ablation technology. The multi-center observational study, which is being conducted at seven sites across the U.S. in up to 50 women, is designed to assess uterine cavity access as well as the feasibility of diagnostic and therapeutic interventions

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, has announced that results from a 12-month prospective, multicenter, pivotal study of its AEGEA Vapor System were published in the peer-reviewed Journal of Minimally Invasive Gynecology

AEGEA Medical announced it has completed enrollment in the Post-Ablation Cavity Evaluation (PACE II) clinical study in women who previously underwent endometrial ablation as part of a pivotal trial of AEGEA’s Adaptive Vapor Ablation technology. The multi-center observational study enrolled 50 women at seven sites across the U.S.

AEGEA Medical Inc. (“AEGEA”), a privately held medical technology company in the women’s health space focused on the development of its patented Adaptive Vapor Ablation technology for endometrial ablation, today announced it has closed on a $30 million financing with Perceptive Advisors (“Perceptive”). In connection with the financing

AEGEA Medical, Inc., a privately held medical device company focused on the development of its patented Adaptive Vapor Ablation technology, today announced U.S. FDA approval of the AEGEA Vapor System as a new treatment option for menorrhagia. The AEGEA Vapor System is the first endometrial ablation system specifically designed for use in